Qiagen N.V. (QGEN) News
Filter QGEN News Items
QGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QGEN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest QGEN News From Around the Web
Below are the latest news stories about QIAGEN NV that investors may wish to consider to help them evaluate QGEN as an investment opportunity.
Qiage announces $300M buyback planMore on Qiagen |
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share RepurchaseVENLO, Netherlands, January 12, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. |
Qiagen scoops FDA clearance for gastrointestinal panelQIAstat-Dx uses real-time PCR technology to multiply genetic targets within the same reaction and deliver test results in around one hour. |
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological SamplesVENLO, Netherlands, January 10, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample. |
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient careGERMANTOWN, Md., & VENLO, The Netherlands, January 09, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. |
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
QGEN Stock Might Rise Following Partnership With Genomics EnglandQIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content. |
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic ContentREDWOOD CITY, Calif. & VENLO, The Netherlands, January 07, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study. |
Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In?We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Qiagen N.V. (NYSE:QGEN) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge […] |
New Product Offerings Support QIAGEN's Shares Amid Currency WoesTo support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms. |